Trial
NCT04637555
Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)
Phase IIIWITHDRAWNEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Post Myocardial Infarction
Intervention
sacubitril/valsartan
Why stopped
CLCZ696G2301E1 extension study did not start as the core study (CLCZ696G2301) did not meet the primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-26